Over the course of the first half of 2004, Gilead limitedįulfillment of orders of Viread(R) (tenofovir disoproxil fumarate) toĮach of the major wholesalers to levels consistent with estimatedĮnd-user demand to prevent the build-up of excess inventory. Terms to our wholesalers, with whom we value our strong Long-term value to Gilead and our shareholders, while providing fair These mutually beneficial agreements will be an important component of PhD, Gilead's President and Chief Executive Officer. 'We are pleased to have completed agreements withĪmerisourceBergen, Cardinal Health and McKesson,' said John C. Processing assistance and counterfeit product detection services.Īdditionally, under the terms of the agreements, each wholesaler hasĪgreed not to exceed specified maximum levels of inventory on hand. Management services, market research information, return goods Wholesalers a fee in exchange for product distribution and inventory Under these agreements, Gilead has agreed to pay the

Help ensure that wholesaler purchasing is consistent with customerĭemand. TheseĪgreements have been implemented to limit speculative buying and to Of the portfolio of products Gilead sells in the United States.

Major pharmaceutical wholesalers that distribute more than 90 percent Inventory management agreements (IMAs) with AmerisourceBergen DrugĬorporation, Cardinal Health, Inc. (Nasdaq:GILD) today announced that it has entered into WholesalersįOSTER CITY, Calif.-(BUSINESS WIRE)-July 12, 2004-Gilead Gilead Signs Inventory Management Agreements with the Three Major U.S. Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Sciences Statement on the Passing of the Honorable George P. Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services

Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer

Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission WadeĪll Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5

Mckesson inventory manager